Amgen Inc.

AMGN · Nasdaq · ·

तुलना करें

$465.73-0.3%13 नव॰ बंद भाव

30 सितंबर 2026 तक के आँकड़े, 4 नवंबर 2026 को दाखिल 10-Q से

1W: +1.2%
1M: +9.3%

Amgen Inc. (AMGN) शेयर — क्या यह अच्छा व्यवसाय है? — InspectStocks

Amgen Inc.

AMGN · Nasdaq · ·

तुलना करें

$465.73-0.3%13 नव॰ बंद भाव

30 सितंबर 2026 तक के आँकड़े, 4 नवंबर 2026 को दाखिल 10-Q से

1W: +1.2%
1M: +9.3%

Just reported

Q3 2026 results

From Amgen's results release of 3 नवंबर 2026; its quarterly report has since been filed.

Revenue
Actual
$10.37B
+8.5% y/y
+3.1% q/q
Guided
—
No guide given
EPS, GAAP
Actual
$7.08
+19% y/y
+62% q/q
Guided
—
No guide given
Operating income, GAAP
Actual
$3.71B
+47% y/y
+5.6% q/q
Guided
—
No guide given

Company outlook

Full year 2026

Revenue$38.9B – $39.7B+6.9% y/y Raised +1.3%
EPS, adjusted$22.90 – $23.70Raised +1.7%
EPS, GAAP$18.34 – $19.28+32% y/y Raised +14%

Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.

Keep exploring

The themes Amgen is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.

The theme it is part of

चयनित
Big pharma
InspectStocks द्वारा · 13 companies
The largest drugmakers, selling prescription medicines worldwide.
भाव, 1 वर्ष
+41.6%
राजस्व, 1 वर्ष
+10.8%
+7
A 7B 3C 3

Highest-graded in Drug Manufacturers General

Graded A or B and worth $2B or more: A first, then the largest.

All 19 graded companies in its industry

Grade rose recently in Healthcare

Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.

All grade rises

कमाई कैसे होती है

Repatha prescription sales9%
Otezla prescription sales7%
Enbrel prescription sales7%
EVENITY prescription sales7%
XGEVA prescription sales6%
TEPEZZA prescription sales6%

आमदनी के हिस्से year ended 2025-12-31, high confidence के अनुमान हैं, किसी दाख़िल रिपोर्ट के आँकड़े नहीं।

मुकाबला किनसे है

क्या बेचती है6

Repatha
An injectable medicine that lowers LDL cholesterol and is used to reduce the chance of major heart and blood-vessel events in certain adults.
Prolia
A medicine for osteoporosis that helps reduce fracture risk in certain people, including postmenopausal women and men at high risk of fracture.
Otezla
An oral medicine used for plaque psoriasis, psoriatic arthritis and certain mouth ulcers.

3 और दिखाएँ

ENBREL
A medicine used for rheumatoid arthritis, plaque psoriasis and psoriatic arthritis.
TEZSPIRE
An antibody medicine used as an add-on treatment for severe uncontrolled asthma and, in approved markets, chronic sinus inflammation with nasal polyps.
IMDELLTRA
A cancer medicine for adults with extensive-stage small cell lung cancer that has progressed during or after platinum-based chemotherapy.

कौन खरीदता है3

In the United States, Amgen sells substantially all its products to pharmaceutical wholesalers, which then distribute them to healthcare providers. McKesson, Cencora and Cardinal Health together accounted for 77% of worldwide gross revenue (year ended 2025-12-31, high confidence).
Outside the United States, Amgen sells to healthcare providers and pharmaceutical wholesalers, depending on local distribution practices.
Healthcare providers, including physicians and their clinics, hospitals, dialysis centers and pharmacies, use or dispense Amgen medicines; some products are also marketed through direct-to-patient channels.

किस पर टिका है, और क्या इसे तोड़ सकता है

कारोबार किन चीज़ों पर टिका है

1Amgen relies on large wholesalers for distribution: McKesson, Cencora and Cardinal Health together accounted for 77% of worldwide gross revenue (year ended 2025-12-31, high confidence).
2The United States is its largest market, accounting for 71.9% of revenue by geography (year ended 2025-12-31, high confidence).
3Its sales depend on government and commercial insurers covering its medicines and deciding how much they will reimburse; coverage rules and required discounts can affect use and net prices.
4The 10-K says a substantial majority of commercial manufacturing takes place in Puerto Rico and a substantial majority of clinical manufacturing takes place in Thousand Oaks, California.
5Amgen relies on third-party suppliers for some raw materials, devices and components, including items for which a supplier may be its only source.

क्या ग़लत हो सकता है

1Government and private payer policies can limit access or reduce the prices Amgen receives. The filings describe Medicare price setting for ENBREL and Otezla, expanded discounts through the 340B program, and other pricing policies as pressures on sales and profitability.
2Biosimilar and generic competition can reduce sales and prices. The patents for Prolia and XGEVA have expired in key markets, and the 10-Q reports lower sales as biosimilar competitors entered those markets.
3Manufacturing disruption could limit medicine supply and sales. The 10-K identifies concentration of commercial manufacturing in Puerto Rico and clinical manufacturing in Thousand Oaks, California, as potential sources of disruption.

पूरे वित्तीय विवरण →

Amgen Inc. के बारे में

Amgen researches, develops and manufactures medicines, including biologic medicines made using living cells and small-molecule drugs. It sells treatments for conditions including heart disease, cancer, osteoporosis, asthma and autoimmune diseases. It also sells biosimilar medicines, which are highly similar versions of existing biologic medicines.

मुख्यालय: Thousand Oaks, California
स्थापना: 1980 (incorporated in California; high confidence)
सूचीबद्ध: NASDAQ
वित्त वर्ष का अंत: December 31

Amgen Inc. की अपनी रिपोर्टों से बना, जो अमेरिकी प्रतिभूति और विनिमय आयोग (SEC) में दाखिल की गईं। आँकड़े जैसे बताए गए, और प्रति-शेयर इतिहास आज के शेयर आधार पर पुनर्गणित। यह एक व्यवसाय का वर्णन है — यह निवेश सलाह नहीं है और न ही कुछ खरीदने या बेचने की सिफ़ारिश।

Just reported